Hyperhidrosis
72 drugs25,552 FAERS reportsMedDRA PT
GET
/api/v1/reaction/hyperhidrosisReference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. The drugs below are ranked by how often this reaction appears on FAERS reports for each drug — high share does not mean the drug caused the reaction, and absence from this list does not mean the reaction never occurred. This is not a symptom checker.
DefinitionNLM MeSH D006945
Excessive sweating. In the localized type, the most frequent sites are the palms, soles, axillae, inguinal folds, and the perineal area. Its chief cause is thought to be emotional. Generalized hyperhidrosis may be induced by a hot, humid environment, by fever, or by vigorous exercise.
Source: U.S. National Library of Medicine — MeSH (Hyperhidrosis)
Drugs reporting Hyperhidrosis (72)
Share = reports listing this reaction ÷ total matched reports for the drug. — means the upstream totals query failed at ingest and the denominator is unknown.
- 1Octopamine1100%
- 2Aldosterone150%
- 3Androsterone150%
- 4Follicle Stimulating Hormone150%
- 5Almotriptan41343%
- 6Trisodium Citrate2,31134%
- 7Dihydroergotamine29625%
- 8Aluminum Zirconium Pentachlorohydrex Gly120%
- 9Pyrophosphate616%
- 10Efbemalenograstim Alfa414%
- 11Copper Gluconate114%
- 12Florbetaben212%
- 13Sulfur Hexafluoride19711%
- 14Fexinidazole110%
- 15Meperidine8759.7%
- 16Nortriptyline5169.2%
- 17Aconite28.3%
- 18Rimantadine27.7%
- 19Hemp17.7%
- 20Nilutamide56.8%
- 21Flutemetamol246.0%
- 22Ferumoxytol1085.7%
- 23Isocarboxazid45.6%
- 24Standardized Senna Concentrate7585.5%
- 25Carboprost385.5%
- 26Ketoprofen6755.3%
- 27Tranylcypromine585.2%
- 28Rutin44.9%
- 29Naloxegol1854.8%
- 30Milnacipran2864.8%
- 31Alvimopan24.7%
- 32Fluorescein414.5%
- 33Ferric Derisomaltose554.4%
- 34Levomilnacipran834.4%
- 35Aluminum Chloride64.4%
- 36Iopromide1654.2%
- 37Pentazocine24.2%
- 38Ketamine1904.1%
- 39Ospemifene1074.1%
- 40Pafolacianine24.1%
- 41Amitriptyline6724.0%
- 42Trimethobenzamide553.9%
- 43Lofexidine63.8%
- 44Duloxetine6,8833.7%
- 45Progesterone8163.6%
- 46Chlorthalidone5193.6%
- 47Levorphanol133.6%
- 48Rizatriptan5603.5%
- 49Xanomeline613.5%
- 50Glycopyrronium513.4%
- 51Motixafortide33.4%
- 52Sincalide53.3%
- 53Mebrofenin33.2%
- 54Relugolix7483.1%
- 55Dextran523.1%
- 56Desvenlafaxine7612.9%
- 57Venlafaxine3,6892.8%
- 58Methylnaltrexone422.8%
- 59Paroxetine2,5062.8%
- 60Cobaltous Chloride12.7%
- 61Perflutren1562.7%
- 62Exametazime12.6%
- 63Flotufolastat12.6%
- 64Solriamfetol942.5%
- 65Selegiline832.4%
- 66Soybean Oil262.4%
- 67Gadobutrol1082.3%
- 68Technetium212.1%
- 69Trospium832.1%
- 70Tetrofosmin122.0%
- 71Regadenoson871.8%
- 72Beta Carotene4—
Related reactions
Other reactions most often co-reported on the same drug set. Ranked by Jaccard similarity over drug-id sets — pure data-derived co-occurrence, not a clinical relationship.
- Flushing14 shared · 0.11
- Loss Of Consciousness12 shared · 0.11
- Chest Discomfort15 shared · 0.10
- Chills17 shared · 0.10
- Feeling Hot8 shared · 0.09
- Unresponsive To Stimuli7 shared · 0.09
- Heart Rate Increased9 shared · 0.09
- Anaphylactic Reaction10 shared · 0.07
- Blood Pressure Decreased8 shared · 0.07
- Hypersensitivity18 shared · 0.07
Literature
Recent PubMed references pinned to Hyperhidrosis as a MeSH major topic. About the reaction term itself — not about any specific drug.
- Risk factors for compensatory hyperhidrosis following CT-guided percutaneous radiofrequency sympathectomy: A retrospective observational study.Medicine · 2026 · Ni C, Han Z, Hua B, et al.PMID 42175438DOI 10.1097/MD.0000000000048976
- [Case report: Spontaneous periodic hypotermia in a geriatric patient].Geriatrie et psychologie neuropsychiatrie du vieillissement · 2026 · Billiet T, Mitha N, Gavazzi G, et al.PMID 42112648DOI 10.1684/pnv.2026.1270
- The use of an objective method (continuous exosomatic electrodermal activity without external stimuli) to evaluate patients with hyperhidrosis undergoing video-assisted sympathectomy.Einstein (Sao Paulo, Brazil) · 2026 · Silveira RJ, Sorbello CCJ, Wolosker N, et al.PMID 42054168DOI 10.31744/einstein_journal/2026AO1266
- Efficacy and Safety of Topical Anticholinergics in the Treatment of Primary Axillary Hyperhidrosis: A Systematic Review and Meta-analysis.Clinical drug investigation · 2026 · Kim J, Han N, Koo H, et al.PMID 41989535DOI 10.1007/s40261-026-01550-2
- Oxybutynin treatment for episodic hyperhidrosis in Parkinson disease.Journal of Parkinson's disease · 2026 · LeWitt PAPMID 41944203DOI 10.1177/1877718X261440704
- Advances in pharmacological treatment and management of hyperhidrosis.Expert opinion on pharmacotherapy · 2026 · Rossi A, Gioacchini H, Marani A, et al.PMID 41871366DOI 10.1080/14656566.2026.2642213
Note. FAERS reports are voluntarily submitted and are NOT incidence rates, signals, or causal evidence. Counts reflect reporting volume, not how often a reaction occurs. Reference statistics only.